Filing Flows › Alnylam Pharmaceuticals (ALNY) › Q1 2025
Alnylam Pharmaceuticals (ALNY) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 1, 2025
Alnylam Pharmaceuticals (ALNY) reported revenue of $594M for the first quarter 2025 (Q1 2025), +20% from a year earlier and +0.2% from the quarter before. Operating margin was 3.0%, net loss $57.5M (9.7% of revenue).
Alnylam Pharmaceuticals, Q1 2025: revenue $594M (+20% year over year), operating margin 3.0%, net loss $57.5M, operating cash flow −$118M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $594M | +0.2% | +20% |
| Operating profit | $18.1M | — | — |
| Net earnings | −$57.5M | — | — |
| Operating cash flow | −$118M | — | — |
What changed
Revenue was $594.2M in Q1 2025, up 20% year over year and roughly flat from the previous quarter. AMVUTTRA was the largest line at 52% of revenue. AMVUTTRA added $114.8M year over year (up 59%), 115% of the total change. ONPATTRO declined 29%.
Operating profit was $18.1M, a 3.0% margin (up 11.8 points year over year). Total costs grew 7% against revenue growth of 20%. The fastest-growing cost line was Cost of revenue (+29%). The quarter ended with a net loss of $57.5M, narrower than the previous quarter's $83.8M loss. Net interest and other expense of $59.7M was the main reason.
Operating cash flow was −$118.3M. Non-cash charges added back $14.4M of depreciation and amortization and $56.7M of share-based compensation. Working capital and other items used $132.0M. Capital expenditures of $9.0M exceeded it, leaving free cash flow of −$127.3M.
Questions
What was Alnylam Pharmaceuticals' revenue in the first quarter 2025?
Alnylam Pharmaceuticals (ALNY) reported revenue of $594M for the first quarter 2025 (Q1 2025), +20% from a year earlier and +0.2% from the quarter before.
Was Alnylam Pharmaceuticals profitable in the first quarter 2025?
Operating profit was $18.1M (3.0% of revenue) and net loss $57.5M.